Sign up to save your podcasts
Or
Share Can Noom rediscover its ad spend glory?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Can Noom rediscover its ad spend glory?
When you look across the vast, ever-expanding GLP-1 landscape, you see a handful of key players with different services offered.
One of them is Noom, which attempts to differentiate itself from other telehealth shops by billing itself as a “behavior-change company.”
Simply put, Noom takes a lifestyle-based approach to weight loss, delving into the habits of its users and reorienting them towards healthier routines for diet and exercise. Building off that foundation, Noom then got into the GLP-1 prescription business in 2023.
Armed with a subscription-based health app and a substantial ad spend for campaigns featuring celebrity spokesperson Rebel Wilson, Noom has raised nearly $660 million over 10 funding rounds since its founding in 2008.
Yet like Weight Watchers, the company’s pivot in the age of GLP-1s hasn’t been without bumps along the way.
Noom conducted mass layoffs in 2022 and 2025 amid a slowdown in its key business units. Still, the company is trudging forward.
This week, Noom CEO Geoff Cook returns to the show to chat with reporter Bella Czajkowski about the company’s plans for the future, how the GLP-1 treatment space needs to evolve and what their go-forward advertising strategy is.
For our Trends segment, we’re talking about a pair of recent Supreme Court rulings – the ‘skinny label’ case between Hikma and Amarin as well as Bayer’s Roundup decision – and what they mean for the healthcare industry.
Ahead of our feature interview, you’ll hear from editorial director Jameson Fleming, who is back from his weeklong trip to cover Cannes. He’s got a full rundown of what you need to know about how medical marketing’s top work was received over there.
Check us out at: mmm-online.com
Follow us:
YouTube: @MMM-online
TikTok: @MMMnews
Instagram: @MMMnewsonline
Twitter/X: @MMMnews
LinkedIn: MM+M
To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
View all episodes
By The MM+M Podcast
4.2
1010 ratings
When you look across the vast, ever-expanding GLP-1 landscape, you see a handful of key players with different services offered.
One of them is Noom, which attempts to differentiate itself from other telehealth shops by billing itself as a “behavior-change company.”
Simply put, Noom takes a lifestyle-based approach to weight loss, delving into the habits of its users and reorienting them towards healthier routines for diet and exercise. Building off that foundation, Noom then got into the GLP-1 prescription business in 2023.
Armed with a subscription-based health app and a substantial ad spend for campaigns featuring celebrity spokesperson Rebel Wilson, Noom has raised nearly $660 million over 10 funding rounds since its founding in 2008.
Yet like Weight Watchers, the company’s pivot in the age of GLP-1s hasn’t been without bumps along the way.
Noom conducted mass layoffs in 2022 and 2025 amid a slowdown in its key business units. Still, the company is trudging forward.
This week, Noom CEO Geoff Cook returns to the show to chat with reporter Bella Czajkowski about the company’s plans for the future, how the GLP-1 treatment space needs to evolve and what their go-forward advertising strategy is.
For our Trends segment, we’re talking about a pair of recent Supreme Court rulings – the ‘skinny label’ case between Hikma and Amarin as well as Bayer’s Roundup decision – and what they mean for the healthcare industry.
Ahead of our feature interview, you’ll hear from editorial director Jameson Fleming, who is back from his weeklong trip to cover Cannes. He’s got a full rundown of what you need to know about how medical marketing’s top work was received over there.
Check us out at: mmm-online.com
Follow us:
YouTube: @MMM-online
TikTok: @MMMnews
Instagram: @MMMnewsonline
Twitter/X: @MMMnews
LinkedIn: MM+M
To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More shows like The MM+M Podcast
View all
The Daily
111,948 Listeners